Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.46) by 102.17 percent. This is a 55.07 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $17.64 million which beat the analyst consensus estimate of $16.15 million by 9.22 percent. This is a 36.39 percent increase over sales of $12.93 million the same period last year.